On July 10, according to a spokesman for the EU anti-monopoly agency, the Japanese Canon Group may be subject to EU anti-monopoly investigations and impose a fine of 2.9 billion US dollars. This is the second international investigation after Canon’s acquisition of Toshiba’s medical system. The EU antitrust agency said that Canon had registered with the European Union after completing its acquisition of Toshiba Medical Systems, and this may have violated relevant regulations and formed a monopoly, which may impose a maximum annual revenue of 10% on the company. Fine.
In addition to Canon, GE, German pharmaceutical giants Merck KGaA and Sigma-Aldrich are also warned by the EU for the same reasons and may face fines. Canon said it will respond at the appropriate time and will not comment until the EU makes a decision.
It is reported that Toshiba Medical System was a high-quality subsidiary of Toshiba, mainly engaged in the manufacture and sales of medical devices such as magnetic resonance imaging (MRI) and X-ray inspection instruments. In March last year, Toshiba, which was exposed to the financial crisis due to financial fraud, announced the sale of the subsidiary, Fujifilm Holdings and other registrations, and Canon eventually won. In December last year, Canon announced the completion of the acquisition process for Toshiba's medical device subsidiary Toshiba Medical Systems, with an acquisition of approximately 665.5 billion yen.
Tetanus Shot,Tetanus Vaccine,Hepatitis B Injection,Hep B Vaccine
FOSHAN PHARMA CO., LTD. , https://www.foshanmedicine.com